6. Pacira Pharmaceuticals ( PCRX) Company Profile: Pacira is a specialty pharmaceutical company. The company's lead drug candidate is Exparel, a long-acting anesthetic/analgesic product for postsurgical pain management. Return Since IPO: 70.9% IPO Date: Feb. 2 Offer Price: Pacira offered 6 million shares at $7 per share Analyst Consensus: Pacira earns high marks with five "buy" ratings from all five research shops covering the stock. They include Piper Jaffray, Wedbush and Brean Murray.